PolyIC as an adjuvant outperforms anti-VEGF in combination with anti-PD-L1 therapy in mouse liver tumor models
This preclinical study identifies polyIC as an efficacious adjuvant of αPD-L1 treatment in liver cancer, providing a better strategy to improve immunotherapy outcomes.
Authors
- Gen‐Sheng Feng (ORCID: https://orcid.org/0000-0003-1255-4708)
- Aiping Qin (ORCID: https://orcid.org/0000-0003-0549-4479)
- Yingluo Liu (ORCID: https://orcid.org/0009-0009-5704-063X)
- Yichun Ji (ORCID: https://orcid.org/0000-0001-8313-1871)
- Li‐Chun Lu (ORCID: https://orcid.org/0000-0001-8975-9491)
- Yiming Gao (ORCID: https://orcid.org/0000-0002-2311-7442)
- Hao Zhuang (ORCID: https://orcid.org/0000-0002-7339-8211)
- Jin Lee (ORCID: https://orcid.org/0000-0001-5815-9848)
Institutions
- University of California San Diego (US)
- National Taiwan University Hospital (TW)
- Henan Cancer Hospital (CN)
- First Affiliated Hospital of Wannan Medical College (CN)
Publication Details
- Journal
- Hepatology Communications
- Published
- 2025-08-15
- DOI
- https://doi.org/10.1097/hc9.0000000000000776
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- National Institutes of Health
- University of California, San Diego